Which hedge funds own SPRY? ARS PHARMACEUTICALS INC, Q2 2026 13F holders
33 tracked hedge funds disclosed a position in SPRY (ARS PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $392.0m in total. The largest holder by portfolio weight is Tyro Capital Management LLC at 8.0% of its book. 10 opened a new position this quarter: Ishara Investments LP, Parkman Healthcare Partners LLC, Quarry LP, Trexquant Investment LP. 9 exited: Wexford Capital LP, Landscape Capital Management, L.L.C., Alpine Woods Capital Investors, LLC.
- 33
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 10
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 9
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $5.7m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $4.0m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $392m
- Combined value Sum of the holders' reported positions in the security.
- 2.7%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Wexford Capital LP | 0.2% | $1.0m |
| Landscape Capital Management, L.L.C. | 0.09% | $1.4m |
| Alpine Woods Capital Investors, LLC | 0.02% | $80.3k |
| ExodusPoint Capital Management, LP | 0.01% | $772k |
| Brevan Howard Capital Management LP | 0.0% | $374k |
| Aquatic Capital Management LLC | 0.0% | $111k |
| Y-Intercept (Hong Kong) Ltd | 0.0% | $128k |
| D. E. Shaw & Co., Inc. | 0.0% | $95.3k |
| Freestone Grove Partners LP | 0.0% | $16 |
Ownership over time
Who discovered SPRY first? Beta
The run: Q3 2023 → Q2 2025, +362%
| Sio Capital Management, LLC | Q2 2023 | 1.3% | +1.1 pts |
| Deerfield Management Company, L.P. | Q4 2022 | 0.9% | +0.3 pts |
| Rubric Capital Management LP | Q4 2022 | 0.1% | −0.2 pts |
| Orbimed Advisors LLC | Q4 2022 | 0.7% | −2.8 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.